OncoMatch/Clinical Trials/NCT06528847
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
Is NCT06528847 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Benmelstobart for non-small cell lung cancer.
Treatment: Benmelstobart — This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) expression ≥1% (≥1%)
Required: EGFR wild-type
Disease stage
Required: Stage IB
Grade: 3 (iaslc pathology committee 2020)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic chemotherapy
No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy
Cannot have received: immunotherapy
No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy
Cannot have received: radiation therapy
No prior receipt of any anti-tumor treatment, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy
Cannot have received: immune checkpoint inhibitor
History of using any antibodies or drugs targeting T-cell co-regulatory proteins (immune checkpoints), or previous treatment with anti-tumor vaccines
Cannot have received: anti-tumor vaccine
previous treatment with anti-tumor vaccines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06528847 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression ≥1% is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IB is required.
Is there an age limit?
Yes. Patients must be 74 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify